ImageneBio, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ImageneBio, Inc. (IMA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $911.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- ImageneBio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $911.00K, a 98.91% increase year-over-year.
- ImageneBio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $876.00K, a 1436.84% increase year-over-year.
- ImageneBio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $15.28M, a 1402.75% increase year-over-year.
- ImageneBio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $458.00K, a 64.19% decline year-over-year.
- ImageneBio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $15.39M, a 190.67% increase from fiscal 2024.
- ImageneBio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $5.29M, a 30.62% decline from fiscal 2023.
- ImageneBio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $7.63M, a 1.42% increase from fiscal 2022.
- ImageneBio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $7.53M, a 45.35% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $911.00K 10-Q · filed 2026-08-05 | $1.79M derived: sum of 2 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $876.00K 10-Q · filed 2026-08-05 | ||||
| 2025-12-31 | $15.39M 10-K · filed 2026-03-10 | ||||
| 2025-09-30 | $15.28M 10-Q · filed 2025-11-12 | $15.74M derived: sum of 2 quarters · filed 2025-11-12 | $15.80M derived: sum of 3 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $458.00K 10-Q · filed 2025-07-24 | $515.00K derived: sum of 2 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $57.00K 10-Q · filed 2026-08-05 | $904.00K 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $5.29M 10-K · filed 2025-03-06 | ||||
| 2024-09-30 | $1.02M 10-Q · filed 2024-11-07 | $2.30M derived: sum of 2 quarters · filed 2025-07-24 | $4.30M derived: sum of 3 quarters · filed 2025-07-24 | ||
| 2024-06-30 | $1.28M 10-Q · filed 2025-07-24 | $3.28M derived: sum of 2 quarters · filed 2025-07-24 | |||
| 2024-03-31 | $2.00M 10-Q · filed 2025-07-24 | ||||
| 2023-12-31 | $7.63M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | $2.00M 10-Q · filed 2024-11-07 | $3.88M derived: sum of 2 quarters · filed 2024-11-07 | $5.88M derived: sum of 3 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $1.88M 10-Q · filed 2024-11-07 | $3.88M derived: sum of 2 quarters · filed 2024-11-07 | |||
| 2023-03-31 | $2.00M 10-Q · filed 2024-11-07 | ||||
| 2022-12-31 | $7.53M 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | $1.81M 10-Q · filed 2023-11-09 | $3.77M derived: sum of 2 quarters · filed 2023-11-09 | $5.67M derived: sum of 3 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $1.96M 10-Q · filed 2023-11-09 | $3.85M derived: sum of 2 quarters · filed 2023-11-09 | |||
| 2022-03-31 | $1.90M 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | $5.18M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $1.45M 10-Q · filed 2022-11-07 | $2.71M derived: sum of 2 quarters · filed 2022-11-07 | $3.60M derived: sum of 3 quarters · filed 2022-11-07 | ||
| 2021-06-30 | $1.26M 10-Q · filed 2022-11-07 | $2.15M derived: sum of 2 quarters · filed 2022-11-07 | |||
| 2021-03-31 | $885.00K 10-Q · filed 2022-11-07 | ||||
| 2020-12-31 | $1.80M 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $418.00K 10-Q · filed 2021-11-10 | $772.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.15M derived: sum of 3 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $354.00K 10-Q · filed 2021-11-10 | $729.00K derived: sum of 2 quarters · filed 2021-11-10 | |||
| 2020-03-31 | $375.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |